Navigation Links
Verenium To Present At Two Upcoming Conferences
Date:5/23/2013

ements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates (including, in each case, their value, potential for revenue growth and expected near-term and longer term revenue)and product pipeline (including the timing for commercial launch of any product candidates), lines of business, operations (including Verenium's ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance (including all financial guidance), and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any comm
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group of ... teaming up with the Heartland Blood Center and offering free ... The drive takes place Saturday, Jan. 18 at the Bill ... p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... selected by Buffalo BioBlower Technologies LLC ("B3") as the ... Phase 2 award from the Army Corps of Engineers.  ... that kills all biological contaminants and destroys VOCs and ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... Jan. 15, 2014 ­ RedBrick Health , a ... technology, today announces that EmblemHealth , the ... company, is now providing the RedBrick Compass health assessment, ... to all of its members. EmblemHealth is among the ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... not just because they sparkle. Engineers and physicists ... is as hard as an ice ball to the ... making it an ideal material or coating for seals, ... Carpick, associate professor in the Department of Mechanical Engineering ...
... Physicists at UC Riverside have made an accidental ... change how information in computers can be transported ... a property electrons possess that makes them behave ... the development of spin-based semiconductor technology such as ...
... Inc.,(Nasdaq: RDYN ) today announced that it has ... Ltd. for faropenem medoxomil (faropenem).,In conjunction with this decision, ... agreement with Asubio Pharma Co., Ltd. and Nippon,Soda Co. ... as a,result of the Company being unable to secure ...
Cached Biology Technology:University of Pennsylvania engineers reveal what makes diamonds slippery at the nanoscale 2Discovery by UC Riverside physicists could enable development of faster computers 2Discovery by UC Riverside physicists could enable development of faster computers 3Replidyne Terminates Faropenem Agreements 2Replidyne Terminates Faropenem Agreements 3
(Date:4/23/2014)... Alzheimer,s disease is the first cause of dementia and ... effective cure has yet been found. One of the ... the cellular mechanisms which cause alterations in nerve transmissions ... of the disease., Researchers from the Institute of Neuroscience ... cellular mechanism involved in memory consolidation and were able ...
(Date:4/23/2014)... University of Liverpool is leading a 2 million Food ... norovirus in food premises and industry workers. , ... In 2012 a batch of frozen strawberries infected ... in the authorities, understanding of which strains cause infection ... the bacteria. , Researchers will produce data ...
(Date:4/22/2014)... the University of Montana,s Wildlife Biology Program, co-wrote a research ... National Academy of Sciences on how streamwater chemistry varies ... Lowe and ... of Washington, the Cary Institute of Ecosystem Studies, the University ... examined 664 water samples collected every 10 meters along 32 ...
Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2New research focuses on streamwater chemistry, landscape variation 2
... on a unique vertebrate called the sea lamprey shows that ... development. These genes are paradoxically lost all throughout the developing ... or PGCs. The PGCs can be thought of as embryonic ... generation of lampreys. Based on computational analysis, a significant number ...
... An inexpensive antifungal drug, thiabendazole, slows tumor growth and shows ... of Natural Sciences at The University of Texas at Austin ... frogs, mice and humans. Thiabendazole is an FDA-approved, generic ... 40 years as an antifungal. It is not currently used ...
... 2012) What comes naturally to most people to ... who have lost the full use of their limbs. New ... TIRR Memorial Hermann aims to help victims recover that ability ... from the National Institutes of Health (NIH) and the President,s ...
Cached Biology News:Research reveals unique solution to gene regulation 2Common antifungal drug decreases tumor growth and shows promise as cancer therapy 2Brain-wave-reading robot might help stroke patients 2Brain-wave-reading robot might help stroke patients 3
Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
Pooled normal sreum with 0.1% sodium azide as preservative...
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Mouse P-Selectin/CD62P MAb (Clone 127933)...
Biology Products: